On the other hand, the studies that failed to find an association between testosterone and CRP used an older population group. Given the conflicting evidence regarding the association between levels of endogenous testosterone and hsCRP, no conclusion can be made on this matter. Although several authors have discovered statistically significant negative associations between levels of endogenous testosterone and CRP,46,92–96 others have failed to demonstrate any association between testosterone and CRP levels.84,97–99 Low testosterone can also develop with age, even without a clear medical condition. The pituitary gland and hypothalamus control how much testosterone the body makes. It can happen due to injury, infection, genetic problems like Klinefelter syndrome, or damage from cancer treatments like radiation or chemotherapy. It has been shown that those with advanced CHF have a higher percentage of type II muscle fibers, based on muscle biopsy.145 Given that no study has found LVEF to improve with testosterone replacement therapy,140–143 it is reasonable to consider that testosterone may be positively affecting exercise capacity involving a peripheral mechanism such as the skeletal muscles. In addition, major adverse cardiovascular events (MACE) were evenly distributed among the 2 groups, with the testosterone replacement group experiencing 7% of the total major adverse cardiovascular events compared with 6% for the placebo group.144 The association between testosterone levels and exercise capacity retained its statistical significance after adjustment for lean tissue mass in the leg. Low testosterone levels can lead to fatigue, low energy, and sometimes problems with heart function. Besides its effects on muscles, bones, and mood, testosterone also influences the heart and blood vessels. When these symptoms are combined with low testosterone levels confirmed by blood tests, TRT may be considered. Testosterone Replacement Therapy, or TRT, is a medical treatment used to raise testosterone levels in men who have low amounts of this hormone. This article looks closely at the possible link between TRT and increased heart rate. This has led many people to wonder if testosterone therapy can cause a fast heart rate or lead to other heart-related problems. In a study of 2078 men who were referred for coronary angiography, Wehr et al discovered an independent association between low levels of free testosterone and CHF mortality.138 Wehr reported the hazard ratio for CHF mortality in the fourth compared with the first quartile of free testosterone to be 0.38 (95% CI, 0.17 to 0.87). To the best of our knowledge, there are no published studies that evaluate the effects of testosterone replacement therapy on IMT. Again, Hak et al did not find a significant association between testosterone levels and progression of atherosclerosis in the female abdominal aorta.133 Demirbag et al performed similar analysis on 42 men, but instead investigated the association between testosterone and thoracic aorta IMT.134 Demirbag et al discovered an inverse association between total testosterone and thoracic aorta IMT.134 BMI indicates body mass index; BP, blood pressure; CCS, case–control study; CS, cross‐sectional study; FT, free testosterone; IMT, intima‐media thickness; SHBG, sex hormone–binding globulin; TT, total testosterone. High testosterone can have several potential symptoms. However, men who are on testosterone blockers, such as those with prostate cancer, also experience rises in cholesterol. Testosterone can have a significant role in many parts of your body, including your heart. Moreover, there must be further investigation into mechanisms of action of testosterone. The opposite directional relationship has also been suggested, such that adiposity may decrease testosterone production. Cumulative incidence did not differ between the 2 groups.47 These studies led the American Health Association, the American Cancer Society, and the American Urological Association48 to issue a joint statement in 2010, declaring it to be "appropriate to state that there may be a relation between ADT and cardiovascular risk." Soon after, the FDA also mandated the addition of warnings of increased risk of diabetes and CVD as a result of GnRH agonist use in men with prostate cancer.49 The effects of the artificial lowering of testosterone levels by ADT on an individual's overall health has also been studied extensively. Adequately powered randomized clinical trials designed to assess cardiovascular events are required to definitively determine the effect of testosterone therapy on cardiovascular risk. In contrast to these studies, others have reported a protective effect of testosterone therapy on cardiovascular health. In men aged 28 Further supporting these results, the Testosterone Trials (TTrials) found a statistically significant 1-year increase in noncalcified plaque volume (estimated difference 41 mm3 95% CI 14 to 67 mm3) in hypogonadal elderly men receiving testosterone therapy, compared to the placebo group.29 No statistically significant difference was found between the intervention and control groups in the number of cardiovascular events or the calcified plaque progression.29 However, the authors indicated that the data may have been influenced by publication bias.19 A meta-analysis by Araujo et al.20 also found an association between testosterone and overall mortality; however, significant heterogeneity between studies suggested that the effects may have been driven by cohort differences.